Sinovac Life Sciences Co., Ltd.
Clinical trials sponsored by Sinovac Life Sciences Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New 24-Valent vaccine aims to shield children from more pneumonia strains Results expected Sep 2026 (estimated)
- New meningitis vaccine enters first human tests Results expected Sep 2026 (estimated)
- New shot aims to block deadly tetanus after dirty wounds Results expected Mar 2027 (estimated) 🚀 Make-or-break
- New baby vaccine could fight pneumonia Results expected Jul 2027 (estimated) 🚀 Make-or-break
-
New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
Vaccine Recruiting nowThis Phase 3 trial is testing a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response compared to an existing vaccine. If it works, i…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New vaccine aims to shield toddlers from 24 pneumonia strains
Vaccine Recruiting nowThis study tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. Around 180 healthy children will receive either the new vaccine or an existing one …
Phase 1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
Vaccine Recruiting nowThis study tests a new vaccine called PCV24 in 420 healthy children aged 2 months to 5 years. The vaccine targets 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. Researchers will compare it to an existing vaccine to see if it is safe …
Phase 2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC